Eli Lilly's value has reportedly reached $1 trillion, driven in part by demand for its weight loss drugs, including GLP-1s. The company's GLP-1 drugs, such as Mounjaro, have seen significant sales, with some reports indicating quarterly sales of $8.7 billion. However, some outlets have also raised concerns about potential risks associated with GLP-1s, including a possible increased risk of vision loss, and the impact of their growing popularity on various industries, including healthcare and food service.